Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

osive growth of clinical research in India. Mr. Maki's presentation is scheduled for 4:25 p.m.

About Cancer Cachexia and VT-122

Cancer cachexia results in severe wasting of muscle and connective tissue and is one of the most common debilitating and distressing conditions of advanced cancer. Severe cachexia is associated with extreme weakness, intolerance to chemotherapy and substantially reduced life expectancy. There is currently no FDA-approved therapy for cancer cachexia.

VT-122 targets inflammatory and other key pathways thought to be responsible for the onset and observed clinical symptoms of cancer cachexia. The use of VT-122 is currently being evaluated under a U.S. IND in a Phase 2 study being conducted concurrently at multiple sites in the U.S. and India. Results from the ongoing trial are expected by end of 2007.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' strategy involves combining individual generic drugs that have previously received regulatory approval for other indications and thus have established post-marketing safety records. Vicus leverages its proprietary science to design and patent novel drug combinations that work together to reverse the body's maladaptive responses to cancer and its treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue. Vicus' development programs are powered by its network of leading clinical investigators and partners in the US, India and Japan. This international network drives the high quality, rapid and cost effective clinical devel
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...CETON, N.J., Nov. 20 Sol... or the Company), formerly known as DOR BioPharma,...ed today that it has formed a consortium to develo... other rapidly acting vaccines. Soligenix received...of Allergy and Infectious Diseases (NIAID), a divi...
(Date:11/19/2009)...INGHAM, Ala., Nov. 19 Bi...y announced the pricing of a public offering of 5,...are, resulting in gross proceeds of $48.75 million... pursuant to an effective shelf registration state...ange Commission. BioCryst has also granted the un...
(Date:11/19/2009)...LAND, Colo., Nov. 19 In ...rs, experience, Heska Corporation (Nasdaq: HSKA )...unch of its new and improved website. The upgrade..., design and programming to align the site with th...es. ,, (Logo: http://www.newscom.com/cgi-bin...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3Croff Enterprises Inc Closes Merger and Will Change Name to Americas Minority Health Network Inc 52860 1Croff Enterprises Inc Closes Merger and Will Change Name to Americas Minority Health Network Inc 52860 2More Dairy Calcium in Childhood Could Mean Longer Life 52856 1More Dairy Calcium in Childhood Could Mean Longer Life 52856 2More Dairy Calcium in Childhood Could Mean Longer Life 52856 3Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 9380 1Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 9380 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 9380 3
...ta Presented at American Psychiatric Association A...ries, Inc.,(NYSE: FRX ) announced today that stud...ificantly improved symptoms of depression as compa... adolescents, aged 12-17, with,major depressive di...d at,the 2008 Annual Meeting of the American Psych...
...Calif., May 7 New Phase 1,clinical trial results ...Nektar Therapeutics (Nasdaq: NKTR ) this week at ...PS) in Tampa, Florida. In this multiple-dose Phase...ial oral bioavailability,with rapid absorption and...,known half-life of unPEGylated naloxone., NKTR-1...
Other Medicine Technology:Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 2Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 3Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 4Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 5Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 6NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 2NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 3NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 4NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 5NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 6
(Date:11/20/2009)...TON, Nov. 20 The Ameri...modify health care reform legislation released thi...alth insurance individual coverage mandate. The ac...date will minimize adverse selection stemming from...d by the bill. ,, "The individual mandate langu...
(Date:11/20/2009)...Nov. 20 The American De...nd Drug Administration (FDA) to establish appropri... ,, Citing concern about the safety of whiteni...e benefit of professional consultation or examinat...plication of chemically based tooth whitening or b...
(Date:11/20/2009)...YORK, Nov. 20 SIRIUS XM ...ill broadcast Doctor Radio Reports: What Every ... special hosted by veteran journalist Perri Peltz....h/20080819/NYTU044LOGO ) ,, Doctor Radio Rep...ams will air November 21 live at 10:00 am ET on...
(Date:11/20/2009)... Based out of Dallas, TX, the new addition to...ucts that are made in the USA. , ...ue sky scrubs is an independent medical scrubs bra... production and distribution of hospital uniforms ...heir products via their online boutique, the Austi...
(Date:11/20/2009)... Longtime OB/GYN warns against the new breast...ntative Services Task Force. These guidelines may ...uman lives. When is it wrong to be safe than sorry...tive Services Task Force recommendations, publishe...edicine, has set off a firestorm in the medical co...
Breaking Medicine News(10 mins):Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Blue Sky Scrubs Secures a Second Texas Manufacturer 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 3
...ent safety, little progress has been made in makin...e specialist Peter Pronovost, M.D., Ph.D., in an a... American Medical Association . , He identifies p...lished To Err Is Human , its treatise on the need...
...ty but not help those with heart rhythm problems ,...Consuming fish oil appears to reduce the chance of...ose with heart rhythm problems, a new analysis sho...ersity of Alberta, in Edmonton, was published in t...
... in neurological vision systems, study shows , ...orts car, a diamond ring, ice cream -- some things...search showing that neural vision systems get turn..."your brain is representing them differently," sai...
...d old alike, , , WEDNESDAY, Dec. 24 (Heal...s joy, which can be a particular concern for peopl...Riba, associate chairwoman for integrated medicine...stions, offered in a news release from the univers...
...ect sponsors HIV charity in Malawi Africa , ...ving decided to help support a charitable cause it...e House of Good Health in Senga Bay, Malawi. Known...Nick Maynard from The Web Project went to Malawi t...
... a leading provider of two way radios and radio eq...nal,s Tekk X1000 series radio as the "Best Ne... Naples, FL (PRWEB) December 23, 20... "Best New Two Way Radio Product of 2008.&qu...
Other Medicine News:Health News:Little progress made in patient safety in spite of Institute of Medicine call to action 2Health News:Bling Makes Your Brain Sing 2Health News:The Web Project visits The House of Good Health in Malawi 2Health News:Fast Radios Names Tekk X1000 Best New Two-Way Radio Product 2
Cervical Retractor Handle - Large
N High Sensitivity CRP
Toothed Pituitary IVD Rongeurs
Micro Decker Pituitary Rongeurs
Medicine Products: